TheraRadar
← Back
Data updated: Mar 29, 2026

BIOCON BIOLOGICS INC

OncologyImmunologyMetabolic
Biotech

BIOCON BIOLOGICS INC is a biotechnology company focused on Oncology, Immunology, Metabolic.

2024
Since
6
Drugs
-
Trials
9
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

YESAFILI 2026-01-13
Manufacturing (CMC)
YESINTEK 2026-01-07
AUKELSO 2025-10-29
Efficacy
AUKELSO 2025-09-16
KIRSTY 2025-07-15
Type 5 - New Formulation or New Manufacturer
YESINTEK 2025-04-30
JOBEVNE 2025-04-09
Type 5 - New Formulation or New Manufacturer
YESINTEK 2024-11-29
Type 2 - New Active Ingredient
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 45%
3 drugs
Immunology 25%
1 drugs Phase 3: 1
Metabolic 15%
1 drugs
Gastroenterology 15%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Immunology, Gastroenterology
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Metabolic
Merck big-pharma
Oncology, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Metabolic
ASTELLAS specialty
Oncology, Gastroenterology, Metabolic, Immunology